Clinical Trials Logo

Clinical Trial Details — Status: Completed

Administrative data

NCT number NCT04150224
Other study ID # PBTZ169-Z00-C01-3
Secondary ID
Status Completed
Phase Phase 1
First received
Last updated
Start date July 3, 2018
Est. completion date February 1, 2019

Study information

Verified date February 2020
Source Nearmedic Plus LLC
Contact n/a
Is FDA regulated No
Health authority
Study type Interventional

Clinical Trial Summary

Open-label prospective non-comparative ascending dose randomized cohort study of single and multiple oral administration of PBTZ169 (capsules 80 mg) in healthy volunteers


Description:

Open-label prospective non-comparativerandomized cohort study of safety, tolerability, pharmacokinetics and the effect of food of PBTZ169 in adult healthy volunteers after single and multiple oral administration. Study was conducted in one study center in the Russian Federation. The study included two stages:

Stage 1 - single or double oral administration with dose escalation (fasted/after meal) in 5 cohorts 10 healthy volunteers each plus 5 back-up volunteers;

Stage 2 - multiple oral administration once a day after meal for 14 days in 1 cohort of 10 healthy volunteers.


Recruitment information / eligibility

Status Completed
Enrollment 60
Est. completion date February 1, 2019
Est. primary completion date November 23, 2018
Accepts healthy volunteers Accepts Healthy Volunteers
Gender All
Age group 18 Years to 45 Years
Eligibility Inclusion Criteria:

1. Written informed consent from the volunteer.

2. Men and women aged 18-45 years, inclusive.

3. Body mass index of 18.5-30 kg/m2.

4. Verified "healthy" diagnosis based on physical examination, vital signs, standard laboratory tests (complete blood count and biochemical blood test, urine analysis) and instrumental tests (ECG, fluorography examination or X-ray examination).

5. Negative results of tests for human immunodeficiency virus (HIV), syphilis, hepatitis B (Hbs Ag) and hepatitis C (antibodies to HCV).

6. Ability to comply with all the requirements of the protocol in the opinion of the investigator.

7. Consent of the participant and his/her partner to use reliable contraceptive methods during the study and within 90 days after the end of their participation. A reliable method of contraception is a combination of a male condom with at least one of the following methods:

- hormonal contraceptives used by the male's partner (only if she does not participate in this clinical study);

- use of aerosols, creams, suppositories and other agents containing spermicides;

- use of intrauterine device by female partner.

Exclusion Criteria:

1. History of allergies, including at least one episode of allergy to medications.

2. Chronic diseases of the cardiovascular, bronchopulmonary, neuroendocrine systems, ENT, as well as diseases of the gastrointestinal tract, liver, kidneys, blood, skin.

3. Hypolactasia (lactose intolerance, lactase deficiency) or glucose-galatose malabsorption in medical history.

4. Chronic eye diseases except for myopia, hypermetropia and astigmatism of mild and moderate severity.

5. Surgeries on the gastrointestinal tract (except for appendectomy done more than 1 year before screening).

6. Regular administration or use (including externally) of hormonal agent for more than 1 week less than 45 days before screening

7. Regular administration of medicinal products less than 4 weeks before screening.

8. Use of medicinal products that have a pronounced effect on liver function or hemodynamics (barbiturates, omeprazole, cimetidine, etc.) less than 30 days before screening.

9. Positive test for narcotics and psychotropic products.

10. Blood pressure after resting in supine position for at least 5 minutes above 130 mm Hg (systolic blood pressure) and 90 mm Hg (diastolic blood pressure) or below 110 mm Hg (systolic blood pressure) and 60 mm Hg (diastolic blood pressure).

11. Heart rate (according to ECG) after resting in supine position for at least 5 minutes above 90 bpm or below 60 bpm.

12. Blood donation (450 mL of blood or plasma and more) less than 3 months before the screening.

13. Acute infectious diseases less than 4 weeks before screening.

14. Administration of more than 10 units of alcohol per week (1 unit of alcohol is equivalent to 500 mL of beer, 200 mL of wine or 50 mL of a spirit) or history of alcoholism, drug abuse, substance abuse.

15. Mental diseases.

16. Smoking for three months before screening.

17. Participation in any clinical study less than 3 months before screening.

18. Planned conception or sperm donation during the study after the administration of the investigational product or within 3 months after the last administration of the product.

19. Positive pregnancy test for women.

20. Breastfeeding period.

Study Design


Related Conditions & MeSH terms


Intervention

Drug:
PBTZ169 640 mg OD
Two administrations once a day with a wash-out period: food effect
PBTZ169 640 mg BiD
Twice a day fasted; 1 day of administration
PBTZ169 960 mg SD
Once a day fasted
PBTZ169 1280 mg SD
Once a day fasted
PBTZ169 1280 mg MD
Once a day after meal, 14 doses

Locations

Country Name City State
Russian Federation Clinical hospital at the Yaroslavl station of the Open Joint Stock Company Russian Railways Yaroslavl

Sponsors (1)

Lead Sponsor Collaborator
Nearmedic Plus LLC

Country where clinical trial is conducted

Russian Federation, 

Outcome

Type Measure Description Time frame Safety issue
Primary Number of Adverse Events Safety and tolerability: number of (S)AEs Up to last visit time point: C2, C3, C4 up to Day 7; C1 up to Day 13; C5 up to Day 21 after first drug intake
Primary Number of Subjects With AEs Safety and tolerability: number of subjects with adverse events Up to last visit time point: C2, C3, C4 up to Day 7; C1 up to Day 13; C5 up to Day 21 after first drug intake
Secondary CS Changes in Vital Signs Safety and tolerability:Clinically significant changes in vital signs (blood pressure, HR, body temperature, RR) Up to last visit time point: C2, C3, C4 up to Day 7; C1 up to Day 13; C5 up to Day 21 after first drug intake
Secondary ECG Results (Safety and Tolerability) Clinically significant abnormal deviations in ECG findings Up to last visit time point: C2, C3, C4 up to Day 7; C1 up to Day 13; C5 up to Day 21 after first drug intake
Secondary Laboratory Examinations Results (Safety and Tolerability) Complete blood count, biochemical blood test, urine analysis Up to last visit time point: C2, C3, C4 up to Day 7; C1 up to Day 13; C5 up to Day 21 after first drug intake
Secondary Results of Physical Examination: CS Deviations Safety and tolerability: number of physical examinations with CS deviations in results Up to last visit time point: C2, C3, C4 up to Day 7; C1 up to Day 13; C5 up to Day 21 after first drug intake
Secondary Peak Plasma Concentration (?max) ?max of PBTZ169 at the timepoints:
C1A, C1B, C2 and C4: point 0 (-5 min to -1 min), 0:30, 1:00, 1:30, 2:00, 3:00, 4:00, 6:00, 9:00, 12:00, 24:00, 48:00 and 72:00 (h:min).
C3 (two administrations): point 0 (-5 min to -1 min), 0:30, 1:00, 1:30, 2:00, 3:00, 4:00, 6:00, 9:00, 12:00 (the point before the second administration from -5 min to -1 min), 12:30, 13:00, 13:30, 14:00, 15:00, 16:00, 18:00, 21:00, 24:00, 48:00 , 72:00 (h:min) after the first administration of the medicinal product.
C5 (14 days of intake): 5 minutes before the administration (only until the first dose), 0 min and within 24 h after the administration of the 1st, 7th and last (14th) dose: 0:15, 0:30, 1:00, 1:30, 2:00, 3:00, 4:00, 6:00, 8:00, 10:00, 12:00, 24:00 (h:min after the administration of a dose of the medicinal product); at 48 h and 72 h points after the last (14th) dose of PBTZ169
In the dosing interval (up to 72 hours after the last drug administration)
Secondary Trough Concentration With Repeated Administration (Ctrough) PBTZ169 concentration before drug intake (Days 2 - 15) Up to 72 hours after the last drug administration
Secondary Time to Reach Maximum Concentration (Tmax) Cohort 3: Tmax relative to the time of administration in any dosage interval Up to 72 hours after the last drug administration
Secondary Plasma Half-life Time (T1/2) Up to 72 hours after the last drug administration
Secondary Area Under the Concentration-time Curve (AUC0 t) In the time interval from 0 to time (t) when the last blood sample is collected with a concentration above the limit of quantification.
C5: for the data of Day 14 based on measurements within 72 hours after the last dose administration
Up to 72 hours after the last drug administration
Secondary Area Under the Concentration-time Curve (AUC0-8) In the time interval from 0 to infinity Up to 72 hours after the last drug administration
Secondary Area Under the Concentration-time Curve (AUC0-24) C5 (multiple administration once a day for 14 days): AUC0-24 was calculated based on measurements within 24 hours after PBTZ169 intake In the dosing interval (up to 24 hours after drug administration)
Secondary Total Clearance (Clt/F) Up to 72 hours after the last drug administration
Secondary Volume of Distribution (Vd/F) Up to 72 hours after the last drug administration
Secondary Elimination Constant Kel Up to 72 hours after the last drug administration
Secondary Relative Bioavailability f=AUC0-8(T)/AUC0-8(R); f'=AUC0-t(T)/AUC0-t(R) Test (T) - PBTZ169 640 mg after meals, reference (R) - PBTZ169 640 mg fasted Up to 72 hours after the last drug administration
Secondary Relative Degree of Absorption f"=Cmax(T)/Cmax(R). Test (T) - PBTZ169 640 mg after meals, reference (R) - PBTZ169 640 mg fasted Up to 72 hours after the last drug administration
Secondary Number of Subjects With CS Changes in Vital Signs Safety and tolerability: No. of sbjs with clinically significant changes in vital signs (blood pressure, HR, body temperature, RR) Up to last visit time point: C2, C3, C4 up to Day 7; C1 up to Day 13; C5 up to Day 21 after first drug intake
See also
  Status Clinical Trial Phase
Completed NCT05483998 - A Study to Evaluate Single and Multiple Doses of TLC-2716 in Healthy Participants Phase 1
Recruiting NCT02235012 - Cognitive Biases Under Ketamine N/A
Recruiting NCT02417714 - Prospective Evaluation of Next Generation CT Reconstruction (NextGenIR)
Completed NCT05088343 - Effect of Hetrombopag on the Pharmacokinetics of Rosuvastatin in Healthy Subjects Phase 1
Completed NCT04418973 - Analysis of Breath Volatile Organic Compounds After Dyspnea Induced in the Healthy Subject. N/A
Not yet recruiting NCT06248801 - Vildagliptin and Metformin Tablets 50/1000 mg Relative to GALVUS MET (50mg/1000 mg) Tablets Phase 1
Terminated NCT04068259 - Single Ascending Dose Study of PBI-4547 in Healthy Subjects Phase 1
Completed NCT03279302 - Trial to Evaluate the PK Profile of Glepaglutide (ZP1848) After a Single IV and After Multiple SC Injections in Healthy Subjects Phase 1
Not yet recruiting NCT06233162 - Febuxostat 80 mg Tablets Relative to Feburic® 80 mg Tablets Phase 1
Recruiting NCT04159844 - Evaluation of the Stiffness and Pressure Applied on the Lower Leg by a New Compression Bandage on Healthy Subjects N/A
Completed NCT06137911 - Evaluation of Safety, Tolerability & Pharmacokinetics of JYP0061 in Healthy Adults. Phase 1
Completed NCT04849286 - Measurement of HTL0016878 in Cerebrospinal Fluid Phase 1
Not yet recruiting NCT06233227 - Dutasteride Soft Capsule 0.5 mg Relative to Avodart 0.5 mg Soft Capsule Phase 1
Completed NCT04096157 - A Study to Assess Isavuconazole Following a Single Dose of Isavuconazonium Sulfate Intravenous Solution Via Nasogastric (NG) Tube Compared to a Single Dose of Oral Capsules Under Fasting Conditions in Healthy Participants Phase 1
Completed NCT01200368 - Trial Evaluating a 13-valent Pneumococcal Conjugate Vaccine Given With Diphtheria, Tetanus, and Acellular Pertussis Vaccine (DTaP) in Healthy Japanese Infants Phase 3
Recruiting NCT05805033 - Peri-Implant Soft Tissue Integration in Humans: Influence of Material N/A
Completed NCT04027803 - Comparative Study of Pharmacokinetics, Pharmacodynamics, Safety, and Immunogenicity of Single Intravenous Doses of BCD-148 and Soliris® Phase 1
Recruiting NCT03467880 - Multicenter Study of Impulse Oscillometry in Chinese N/A
Completed NCT02903095 - Single Ascending Dose Study of TD-1439 in Healthy Subjects Phase 1
Active, not recruiting NCT02341508 - A Phase 1a, Double-Blind, Placebo-Controlled, Single Ascending Dose Study to Evaluate Lpathomab in Healthy Volunteers Phase 1